Arca
Skip to content
Tools
Tools

NT5E: 5'-nucleotidase

Catalyzes the hydrolysis of nucleotide monophosphates, releasing inorganic phosphate and the corresponding nucleoside, with AMP being the preferred substrate.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on NT5E, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1

Approved0

    Phase 31

    • Oleclumab

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        OleclumabPhase 3AstraZeneca PharmaceuticalsAntibodyInhibitor5'-nucleotidase inhibitor14

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2OleclumabPhase 2Not yet recruitingMontefiore Medical CenterAug 28, 2025
        A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)OleclumabPhase 2Active, not recruitingAstraZenecaSep 23, 2024
        Durvalumab and Oleclumab in Resectable PDACOleclumabPhase 2RecruitingUniversity Health Network, TorontoSep 29, 2023
        A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerOleclumabPhase 3Active, not recruitingAstraZenecaFeb 3, 2022
        Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerOleclumabPhase 2RecruitingAstraZenecaSep 29, 2021
        Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic CancerOleclumabPhase 2Active, not recruitingM.D. Anderson Cancer CenterJun 25, 2021
        Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaOleclumabPhase 2Active, not recruitingM.D. Anderson Cancer CenterDec 16, 2020
        COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCOleclumabPhase 1 / Phase 2Active, not recruitingMedImmune LLCAug 28, 2019

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Hereditary arterial and articular multiple calcification syndrome0.72
        • Autosomal recessive spinocerebellar ataxia 200.56
        • Spinocerebellar atrophy0.34
        • Non-small cell lung carcinoma0.33
        • Placental abruption0.29
        • Abnormal brain morphology0.27
        • Hereditary disease0.20
        • Pathologic fracture0.19
        • Facial morphology0.16
        • Lower urinary tract calculus0.16

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5957, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P21589, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.